Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Overview | Financials
Company Name Phathom Pharmaceuticals, Inc.
Symbol PHAT
Currency USD
Price 11.08
Market Cap 648,570,016
Dividend Yield 0%
52-week-range 6.065 - 17.019
Industry Biotechnology
Sector Healthcare
CEO Ms. Terrie J. Curran
Website https://www.phathompharma.com

An error occurred while fetching data.

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in

Related Stocks

Zynex, Inc. logo

Zynex, Inc.

ZYXI

9 USD

LianBio logo

LianBio

LIAN

0.319 USD

Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc.

EWTX

17.05 USD

Radius Health, Inc. logo

Radius Health, Inc.

RDUS

14.59 USD

Generation Bio Co. logo

Generation Bio Co.

GBIO

2.75 USD

Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc.

MCRB

0.776 USD

Financials

Numbers are in millions USD

Numbers are in millions USD